These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9160521)

  • 1. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.
    Hurwitz JL; Soike KF; Sangster MY; Portner A; Sealy RE; Dawson DH; Coleclough C
    Vaccine; 1997 Apr; 15(5):533-40. PubMed ID: 9160521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.
    Adderson E; Branum K; Sealy RE; Jones BG; Surman SL; Penkert R; Freiden P; Slobod KS; Gaur AH; Hayden RT; Allison K; Howlett N; Utech J; Allay J; Knight J; Sleep S; Meagher MM; Russell CJ; Portner A; Hurwitz JL
    Clin Vaccine Immunol; 2015 Mar; 22(3):298-303. PubMed ID: 25552633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection.
    Sangster M; Smith FS; Coleclough C; Hurwitz JL
    Virology; 1995 Sep; 212(1):13-9. PubMed ID: 7676623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
    Slobod KS; Shenep JL; Luján-Zilbermann J; Allison K; Brown B; Scroggs RA; Portner A; Coleclough C; Hurwitz JL
    Vaccine; 2004 Aug; 22(23-24):3182-6. PubMed ID: 15297072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
    Scaggs Huang F; Bernstein DI; Slobod KS; Portner A; Takimoto T; Russell CJ; Meagher M; Jones BG; Sealy RE; Coleclough C; Branum K; Dickey M; Buschle K; McNeal M; Makowski M; Nakamura A; Hurwitz JL
    Hum Vaccin Immunother; 2021 Feb; 17(2):554-559. PubMed ID: 32750273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
    Skiadopoulos MH; Surman SR; Riggs JM; Elkins WR; St Claire M; Nishio M; Garcin D; Kolakofsky D; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):153-60. PubMed ID: 12083845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
    Durbin AP; Elkins WR; Murphy BR
    Vaccine; 2000 May; 18(22):2462-9. PubMed ID: 10738104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.
    Sealy R; Jones BG; Surman SL; Hurwitz JL
    Vaccine; 2010 Sep; 28(41):6749-56. PubMed ID: 20682364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.
    Karron RA; Makhene M; Gay K; Wilson MH; Clements ML; Murphy BR
    Pediatr Infect Dis J; 1996 Aug; 15(8):650-4. PubMed ID: 8858666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological response of monkeys infected intranasally with human parainfluenza virus type 4.
    Komada H; Tsurudome M; Bando H; Nishio M; Ueda M; Tsumura H; Ito Y
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3487-92. PubMed ID: 2481714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.
    Takao SI; Kiyotani K; Sakaguchi T; Fujii Y; Seno M; Yoshida T
    J Virol; 1997 Jan; 71(1):832-8. PubMed ID: 8985426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.
    Russell CJ; Hurwitz JL
    Expert Rev Vaccines; 2016; 15(2):189-200. PubMed ID: 26648515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the efficacy of intranasal vaccination for the prevention of experimentally induced parainfluenza type 3 virus pneumonia in calves.
    Bryson DG; Adair BM; McNulty MS; McAliskey M; Bradford HE; Allan GM; Evans RT; Forster F
    Vet Rec; 1999 Jul; 145(2):33-9. PubMed ID: 10458574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study.
    Burke CW; Li M; Hurwitz JL; Vogel P; Russell CJ
    J Virol; 2015 Apr; 89(7):3568-83. PubMed ID: 25589649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation.
    Alymova IV; Watanabe M; Boyd KL; Chand P; Babu YS; Portner A
    Antivir Ther; 2009; 14(7):891-8. PubMed ID: 19918093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.